Zeyi Cheng

Dr. Zeyi Cheng


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2021 in Journal of Cardiac Surgery
Verified
Journal Article
Closed access
PDF file
TWTongyu Wang
Tongyu Wang
AOAixin Ou
Aixin Ou
PXPing Xia
Ping Xia
JTJiahu Tian
Jiahu Tian
HWHongchang Wang
Hongchang Wang
ZCZeyi Cheng
Zeyi Cheng

3 March 2021 in The Heart Surgery Forum
Verified
Journal Article
Closed access
PDF file
ZCZeyi Cheng
Zeyi Cheng
TFTingting Fang
Tingting Fang
DWDandan Wang
Dandan Wang
YGYingqiang Guo
Yingqiang Guo
Background: Tricuspid valve replacement (TVR) is seldom performed in cardiac valve surgery, and there currently are no clinical guidelines as to which type of prostheses is better in tricuspid valve position. This meta-analysis was performed to compare the results of mechanical and biological prostheses for TVR. Methods: We searched the Pubmed, Cochrane, and Embase clinical trial databases to collect all related studies published from January 1, 2000 to July 31, 2020. A random-effects model was used to evaluate the odds ratios (OR) and its 95% confidence intervals (CI) of time-to-event related effects of the surgical procedures; every study’s quality was evaluated by the Newcastle-Ottawa Scale (NOS). Results: A total of 13 retrospective studies, including 1453 patients were analyzed. There were no statistically differences between mechanical and biological prostheses with respect to prosthetic valve failure [OR = 0.84, 95% CI(0.54, 1.28), P = .41], bleeding [OR = 0.84, 95% CI(0.54,1.28), P = .41], reoperation [OR = 1.02, 95% CI(0.58,1.78), P = .95], early mortality [OR = 1.35, 95% CI(0.82,2.25), P = .24] and long-time survival [OR = 1.09, 95% CI(0.70, 1.69), P = .70], but a significant difference can be seen in mechanical prostheses with a higher risk of thrombosis [OR = 0.17, 95% CI(0.05, 0.60), P = .006, I2 = 0%]. Conclusions: In tricuspid valve position, mechanical valve prostheses have a higher risk of thrombosis than biological prostheses, but no statistical differences between mechanical and biological prostheses with respect to prosthetic valve failure, bleeding, reoperation, early mortality, and long-term survival. The valve disease and patient’s age and risk factors are the most important considerations in the decision-making process. The more specific conclusion needs to be further proved by large-sample, multi-center, randomized, double-blind and control trials.

3 June 2022 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
TWTongyu Wang
Tongyu Wang
TFTingting Fang
Tingting Fang
ZCZeyi Cheng
Zeyi Cheng
Introduction: Atrial fibrillation (AF) is a prevalent arrhythmia that occurs in 2–4% of adults and poses a threat to human health. Thus, comparison of the efficacy and safety of therapies for AF is warranted. Here, we used network analysis to compare efficacy (arrhythmia recurrence and re-hospitalization) and safety (ischemic cerebral vascular events, all-cause mortality, and cardiovascular mortality) endpoints among five major therapies for AF.Methods: The PubMed, Cochrane, and Embase databases were searched, and relevant literature was retrieved. Only studies that made comparisons among the therapies of interest and involved patients with AF were included. Pairwise comparisons and frequentist method (SUCRA plot) analyses were conducted.Results: In total, 62 studies were included in the pooled analysis. In pairwise comparisons, atrioventricular nodal ablation plus permanent pacemaker (AVN + PPM) was associated with a significantly higher risk of atrial arrhythmia recurrence than surgical ablation [odds ratio (OR): 23.82, 95% confidence interval (CI): 1.97–287.59, fixed-effect model; 3.82, 95% CI: 1.01–559.74, random-effects model]. Furthermore, radiofrequency ablation was associated with a significantly lower risk of cardiovascular mortality than medication in pairwise comparison (OR: 0.49, 95% CI: 0.29–0.83, fixed-effect model; OR: 0.49, 95% CI: 0.27–0.9, random-effects model). Frequentist analysis indicated that AVN + PPM had the best performance in reducing the risk of safety and efficacy endpoints.Conclusion: Non-pharmaceutical therapies showed superior performance to traditional drug therapy in lowering the risk of safety and efficiency endpoint events. AVN + PPM performed best in reducing the risk of safety and efficacy endpoints.

8 September 2021 in The Heart Surgery Forum
Verified
Journal Article
Closed access
PDF file
ZCZeyi Cheng
Zeyi Cheng
MQMiaomiao Qi
Miaomiao Qi
WZWenji Zhao
Wenji Zhao
TFTingting Fang
Tingting Fang
MAMahboob Alam
Mahboob Alam
YGYingqiang Guo
Yingqiang Guo
Objective: The purpose of this investigation aimed to clarify the impact of peripheral artery disease (PAD) on the prognosis value of patients with stable coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI). Methods: The SPSS 16 software was used for secondary analysis of DRYAD database data. A total of 204 patients were enrolled from Shinonoi General Hospital for newly diagnosed stable CAD and received PCI performance between October 2014 and October 2017. Patients with old myocardial infarction (MI) were excluded. We divided patients into two groups with PAD and without PAD. The primary endpoints were major adverse cardiac events (MACE, defined as all-cause death, non-fatal MI, and non-fatal stroke) and cardiovascular events (defined as cardiovascular death, non-fatal MI, and non-fatal stroke). The secondary outcomes were the individual components of the composite primary outcomes. The median follow-up time was 783 days. Results: No statistical difference was found between PAD and non-PAD patients of lesional characteristics. Spearman’s rank correlations indicate diabetes mellitus (DM) (P = 0.019) and HbA1c (P = 0.009) are positively correlated with PAD. In Kaplan-Meier analysis, patients with PAD predicted poor prognosis in MACE (P < 0.05) and cardiovascular events (P < 0.05). In Multivariable Cox proportional hazards analysis, patients with PAD independently predicted MACE and cardiovascular events. Conclusions: PAD is a significant mediator for the prognosis of patients with stable CAD who underwent PCI treatment.

11 May 2021 in The Heart Surgery Forum
Verified
Journal Article
Closed access
PDF file
ZCZeyi Cheng
Zeyi Cheng
JXJin Xu
Jin Xu
YGYingqiang Guo
Yingqiang Guo
Paraplegia is an unpredictable neurologic complication after coronary artery bypass grafting (CABG) surgery. It is rare but fatal, and the mechanism still is unclear. We aimed to make a summary of the possible causes of paraplegia after CABG. Pubmed database was searched from January 1, 1978 to December 31, 2019, and 14 studies were finally included. Paraplegia after CABG is a multifactorial consequence, but spinal cord ischemia is the key pathological factor to postoperative paraplegia.

5 December 2021 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
YJYupeng Ji
Yupeng Ji
LHLi He
Li He
ZCZeyi Cheng
Zeyi Cheng
JSJun Shi
Jun Shi
LLLulu Liu
Lulu Liu
YGYingqiang Guo
Yingqiang Guo
We report the initial 5‐year follow‐up of a novel mini‐invasive procedure for epicardial ablation for the treatment of atrial fibrillation. The initial 5‐year survival rate is acceptable and comparable with that of hybrid ablation. And this shared procedure has the advantages of shorter operation time and less surgical trauma.